{"title":"Sirtuin-3 Regulates the Mechanism of Doxorubicin-induced Cardiotoxicity.","authors":"Cheng Zhang, Dan Shi, Ping Yang","doi":"10.1536/ihj.24-546","DOIUrl":"https://doi.org/10.1536/ihj.24-546","url":null,"abstract":"<p><p>Doxorubicin (DOX) is a widely used and efficacious anthracycline in clinical practice for the treatment of various tumors; however, a major limitation of DOX therapy is its cardiotoxicity, which significantly restricts its clinical application. Mitochondria in the heart are particularly susceptible to the deleterious effects of DOX, resulting in mitochondrial dysfunction, reactive oxygen species generation, cardiomyocyte apoptosis, bioenergetic failure, and impaired cardiac function. Mitochondrial sirtuins (SIRT3 and SIRT4) play pivotal roles in these cellular processes. Sirtuin-3 (SIRT3), a member of the mitochondrial Sirtuin family, effectively attenuates DOX-induced myocardial injury by suppressing inflammation and oxidative damage while improving mitochondrial function. Therefore, SIRT3 is a key regulator involved in multiple mechanisms underlying DOX-induced cardiotoxicity. Several studies have shown the protective effects of SIRT3 against DOX-induced myocardial injury and have provided insights into its potential for future clinical applications.</p>","PeriodicalId":13711,"journal":{"name":"International heart journal","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144600322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Nicotine Induces Fetal Cardiac Dysfunction by Promoting Cardiomyocyte Apoptosis Through Regulating the KCTD10-Notch Signaling.","authors":"Lilin Zhong, Xiaoqing Yang, Huifen Zhang, Meijiao Fu, Jianxing Cai, Wanting Huang, Ying Huang","doi":"10.1536/ihj.24-427","DOIUrl":"https://doi.org/10.1536/ihj.24-427","url":null,"abstract":"<p><p>Congenital heart defects (CHD) are internal risk factors that cause cardiac dysfunction. Maternal smoking is a cause of inducing CHD and cardiac dysfunction. Here, we aimed to investigate the influence of nicotine on fetal cardiac dysfunction and the underlying mechanism in mice. After maternal nicotine exposure (MNE), the female mice became pregnant, and the successful pregnancy rate was calculated. Fetal weight, cardiac function, and placental weight were measured at embryonic day 18.5. For in vitro experiments, primary cardiomyocytes were isolated. Cell apoptosis and inflammation were analyzed using flow cytometry and enzyme-linked immunosorbent assay. The molecular mechanism was evaluated using molecular docking, quantitative real-time PCR, and western blotting. The results showed that MNE reduced the fetal weight, cardiac function, and maternal pregnancy rate in vivo. Nicotine promotes apoptosis and inflammation of cardiomyocytes in vitro. Moreover, nicotine decreased KCTD10 expression and activated the Notch pathway. Inactivation of the Notch pathway using DAPT reversed the effects of nicotine on cardiomyocyte injury and MNE on fetal cardiac dysfunction. In conclusion, nicotine may promote fetal cardiac dysfunction by facilitating cardiomyocyte apoptosis through the KCTD10-Notch pathway.</p>","PeriodicalId":13711,"journal":{"name":"International heart journal","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144600321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Xuejiao Wu, Fang Liu, Le Jin, Minqi Huo, Jun Chen, Ruirui Song, Xiaojing Shi, Hongmei Gao
{"title":"The Causal Relationship Between Atrial Fibrillation and Work and Sleep.","authors":"Xuejiao Wu, Fang Liu, Le Jin, Minqi Huo, Jun Chen, Ruirui Song, Xiaojing Shi, Hongmei Gao","doi":"10.1536/ihj.24-660","DOIUrl":"https://doi.org/10.1536/ihj.24-660","url":null,"abstract":"<p><p>Atrial fibrillation (AF) is a common arrhythmia that can reduce the quality of life of patients. Observational studies have reported that work and sleep are associated with the development of AF, but the causal relationship is unclear.Based on published genome-wide association studies (GWASs), we conducted a two-sample Mendelian Randomization (MR) analysis employing inverse variance weighted (IVW), weighted median, and MR-Egger regression analyses. We chose statistical data of 3 work factors from the MRC-IEU GWAS pipeline and 2 sleep factors from the Sleep Disorders Knowledge Portal as the exposure and the FinnGen study of AF as the outcome.The study revealed that engaging in heavy physical work was associated with an increased risk of AF (IVW OR, 1.787; 95% CI, 1.082-2.853; P = 0.023), and job satisfaction was negatively correlated with AF risk (IVW OR, 0.719; 95% CI, 0.536-0.964; P = 0.028). In addition, jobs that primarily involved walking or standing, short sleep duration (< 7 hours), and long sleep duration (≥ 9 hours) were not associated with AF. The results of the sensitivity analysis are consistent with these trends.The results support a causal relationship between heavy physical labor and increased risk of AF, and that job satisfaction has some protective effect on AF.</p>","PeriodicalId":13711,"journal":{"name":"International heart journal","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144600323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A Fatal Case of Immune Checkpoint Inhibitor-Associated Myocarditis with Severe Right Ventricular Failure.","authors":"Takuro Imaoka, Kimi Sato, Shingo Sakashita, Yuma Shibutani, Atsuko Suzuki, Daisuke Kotani, Kohei Shitara, Kazuko Tajiri","doi":"10.1536/ihj.24-701","DOIUrl":"10.1536/ihj.24-701","url":null,"abstract":"<p><p>A 70-year-old man with esophageal cancer undergoing nivolumab treatment presented to our hospital with suspected myocarditis associated with immune checkpoint inhibitor (ICI) therapy. The initial echocardiographic assessment upon admission demonstrated a preserved left ventricular (LV) ejection fraction but impaired right ventricular (RV) function. An endomyocardial biopsy revealed significant lymphocytic infiltration and myocyte necrosis. High-dose steroid therapy was initiated on the day of admission. However, on the following day, RV function deteriorated further, and LV dysfunction emerged, resulting in hemodynamic collapse and necessitating mechanical circulatory support. Despite additional immunoglobulin therapy, cardiac function failed to improve, and the patient died 9 days after admission. This case underscores the critical need for vigilant monitoring of both LV and RV function in patients undergoing ICI therapy to detect and manage potential cardiovascular complications promptly.</p>","PeriodicalId":13711,"journal":{"name":"International heart journal","volume":" ","pages":"511-515"},"PeriodicalIF":1.2,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144077736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Clinical Findings after Two Years of Rheocarna<sup>®</sup> Use.","authors":"Akinori Satake, Takahiro Tokuda, Hirofumi Ohashi, Tetsuya Amano","doi":"10.1536/ihj.25-063","DOIUrl":"10.1536/ihj.25-063","url":null,"abstract":"","PeriodicalId":13711,"journal":{"name":"International heart journal","volume":" ","pages":"521-522"},"PeriodicalIF":1.2,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144077738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Vasospastic Angina as a Cause of Post-Acute Sequelae of COVID-19.","authors":"Tadao Aikawa, Jiro Ogino, Naohiro Funayama, Noriko Oyama-Manabe, Tohru Minamino","doi":"10.1536/ihj.24-795","DOIUrl":"10.1536/ihj.24-795","url":null,"abstract":"<p><p>Diagnosing the cause of post-acute sequelae of COVID-19 (PASC, also known as long COVID)-related chest pain is often challenging in patients with a low pre-test probability of coronary artery disease. In a retrospective review of 273 consecutive patients who presented to the cardiovascular outpatient unit for cardiovascular PASC at the Hokkaido Cardiovascular Hospital, Japan, 8 patients were suspected to have vasospastic angina (VSA) and underwent acetylcholine provocation testing, 5 of whom (1.8%, 5/273) were newly diagnosed with VSA. Although the causal relationship between VSA and PASC should be studied further, the present study suggests that VSA can be a potential cause of chest pain in patients with PASC.</p>","PeriodicalId":13711,"journal":{"name":"International heart journal","volume":" ","pages":"504-510"},"PeriodicalIF":1.2,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144077871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Clinical Outcomes of Coronary Computed Tomography Angiography-Derived Fractional Flow Reserve.","authors":"Kota Komiyama, Kengo Tanabe, Eiji Taguchi, Tomohiro Sakamoto, Rine Nakanishi, Ryo Okubo, Akira Saito, Taku Asano, Akihiro Ikuta, Kazushige Kadota, Yui O Nozaki, Shinichiro Fujimoto","doi":"10.1536/ihj.24-534","DOIUrl":"10.1536/ihj.24-534","url":null,"abstract":"<p><p>Coronary computed tomography angiography-derived fractional flow reserve (FFR<sub>CT</sub>) is useful for noninvasively detecting coronary artery disease. This procedure has been covered by health insurance reimbursement in the United Kingdom, the United States of America, and Japan. This is the first study to investigate the 1-year outcomes of the FFR<sub>CT</sub>, with management covered by health insurance from the DiscoverY of Novel Assessment Myocardial IsChemia by FFR<sub>CT</sub> (DYNAMIC-FFR<sub>CT</sub>) registry.In this multicenter DYNAMIC-FFR<sub>CT</sub> registry, 410 participants who underwent FFR<sub>CT</sub> analysis under health insurance reimbursement were prospectively enrolled at six Japanese sites between October 2019 and November 2021. In accordance with recent guidelines, all participants received appropriate revascularization and/or optimal medication therapy after FFR<sub>CT</sub>. The following clinical outcomes through the 1-year defined major adverse cardiovascular event (MACE) were investigated: all-cause death, cardiovascular events including non-fatal myocardial infarction, and unplanned hospitalization for acute coronary syndrome leading to revascularization.Of the six MACE cases, four (1.6%) occurred in participants with an FFR<sub>CT</sub> value ≤ 0.80, whereas two (1.3%) occurred in a participant with an FFR<sub>CT</sub> value > 0.80.This analytical study based on the DYNAMIC-FFR<sub>CT</sub> registry for cardiovascular conditions found no significant difference in 1-year MACE between FFR<sub>CT</sub>≤ 0.80 and > 0.80 following guideline-based therapy. The registry was started shortly after reimbursement and had limited statistical power and selection bias. Further studies with sufficient statistical power are required.</p>","PeriodicalId":13711,"journal":{"name":"International heart journal","volume":" ","pages":"337-344"},"PeriodicalIF":1.2,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144077741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Utility and Limitations of Genetic Testing in the Routine Care of Cardiovascular Disease Patients in a General Hospital.","authors":"Daiki Tomidokoro, Kotaro Mori, Masaya Yamamoto, Masato Isono, Kozue Takano, Atsuko Okazaki, Reiko Arakawa, Fumihiko Takeuchi, Hisao Hara, Yukio Hiroi, Norihiro Kato","doi":"10.1536/ihj.24-667","DOIUrl":"10.1536/ihj.24-667","url":null,"abstract":"<p><p>Genetic diagnosis is becoming more prevalent in the routine care of cardiovascular disease (CVD) but is still limited to specialized institutions. Therefore, general cardiologists are also expected to acquire fundamental knowledge for incorporating genomics into the clinical practice of inherited to multifactorial CVDs. To accomplish this, the present study evaluated the utility and limitations of genetic testing in a general hospital setting.We examined 2 clinical issues: 1) the diagnostic potential of genetic tests for known inherited CVDs across 4 disease entities, i.e., familial hypercholesterolemia (FH), hypertrophic cardiomyopathy (HCM), suspected lethal arrhythmia, and aortic aneurysm/dissection (total n = 84) and 2) the genetic components associated with 2 multifactorial pathologies, cardiac hypertrophy and atrial fibrillation (AF), through a case-control study (total n = 594). We first performed targeted gene panel tests or whole-exome sequencing to identify causative gene variants for inherited CVDs; this yielded a positive test rate of 14 to 40%. The diagnosis rate for FH increased to 70% if strict eligibility criteria were adopted. The diagnosis rate for HCM also markedly increased by modifying the interpretation criteria for genetic variant pathogenicity. Furthermore, we performed gene-based burden tests and polygenic risk score (PRS) calculations for cardiac hypertrophy and AF. For example, the PRS-based genetic risk was significantly increased in early-onset (≤ 60 years) AF compared to non-AF controls (per-SD odds ratio in standardized PRS: 1.83, P = 2.6 × 10<sup>-4</sup>).Genetic tests for CVDs may complement the diagnosis based on traditional laboratory-based diagnostics, although the currently limited capabilities of variant interpretation necessitate careful attention.</p>","PeriodicalId":13711,"journal":{"name":"International heart journal","volume":" ","pages":"375-384"},"PeriodicalIF":1.2,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144077863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Decrease in Caveolae-Gαq Interaction Mediates Pressure Overload-Induced Cardiac Remodeling in Rats.","authors":"Lijin Wang, Lu Yang, Fang Wu, Henglin Wang","doi":"10.1536/ihj.24-734","DOIUrl":"10.1536/ihj.24-734","url":null,"abstract":"<p><p>Despite its significant clinical implications, pressure overload-induced cardiac remodeling is poorly understood. This study aimed to investigate the role of Caveolae-Gαq interaction in the pathophysiology of pressure overload-induced cardiac remodeling. We used the abdominal aortic constriction (AAC) rat model and the angiotensin II-treated cell model to simulate pressure overload-induced cardiac remodeling. Histological changes were assessed using hematoxylin-eosin staining, immunofluorescence staining, and transmission electron microscopy. The expression, colocalization, and calcium response of the Caveolae-Gαq-PLCβ3 signaling pathway were evaluated using western blotting, quantitative real-time PCR, immunofluorescence staining, and calcium green labeling. We found AAC decreased Caveolin-3 expression but increased Gαq and PLCβ3 expressions. Similar trends in mRNA expression levels were observed. The caveolae's ultrastructure was deformed at 4 and 12 weeks after AAC surgery. AAC and angiotensin II treatments reduced Caveolin-3 and Gαq colocalization while increasing Gαq and PLCβ3 colocalization, and prolonging intracellular calcium response after Gαq activation. In conclusion, pressure overload-induced cardiac remodeling involves caveolar deformation and decreased Caveolae-Gαq interactions, which result in enhanced expression and functionality of Gαq-PLCβ3 signaling. These findings highlight the mechanistic importance of Caveolae-Gαq interactions in cardiac hypertrophy under pressure overload conditions.</p>","PeriodicalId":13711,"journal":{"name":"International heart journal","volume":" ","pages":"485-496"},"PeriodicalIF":1.2,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144077757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Real-World Data on Post-Discharge Prognosis of Elderly and Frail Hospitalized Patients with Heart Failure Reflecting the Latest Guideline-Directed Medical Therapy in Japan.","authors":"Susumu Odajima, Keisuke Fujimoto, Akihiro Kadoi, Takafumi Tsuboi, Yoshinori Nagasawa, Kiyohiro Hyogo, Kenzo Uzu, Yoko Fukuoka, Yasushi Shimokawa, Hideaki Okubo, Kazuo Mizutani, Hiroki Shimizu","doi":"10.1536/ihj.24-752","DOIUrl":"10.1536/ihj.24-752","url":null,"abstract":"<p><p>The West Tokyo Heart Failure (WET-HF) registry has recently reported that the post-discharge prognosis for hospitalized patients with heart failure (HF) between 2011 and 2021 has been improving over time and that there has been an upward trend in the use of guideline-directed medical therapy (GDMT). However, there are few post-discharge prognostic data for elderly and frail hospitalized patients with HF. A total of 738 consecutive patients with HF hospitalized at the Konan Medical Center between April 2020 and March 2024 were retrospectively studied. The primary endpoint was cardiovascular death or HF hospitalization. The mean age and clinical frailty scale were 83.4 ± 11.0 years and 4.8 ± 2.3, respectively. The average prescription rates of GDMT at discharge over the 4-year period were 71.0% for beta-blockers, 23.4% for angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARB), 42.7% for angiotensin receptor neprilysin inhibitor (ARNI), 56.1% for mineralocorticoid receptor antagonists (MRA), and 23.2% for sodium-glucose cotransporter 2 (SGLT2) inhibitors. Although, there has been an upward trend in the use of GDMT, the Kaplan-Meier curve showed no improvement in prognosis over time. Multivariate analyses showed that none of the beta-blockers, ACE-I, ARB, ARNI, MRA, or SGLT2-inhibitors at discharge reduced the primary endpoint for hospitalized patients with HF. GDMT alone may not be sufficient to improve the prognosis of elderly and frail hospitalized patients with HF. In addition to GDMT, comprehensive management by a multidisciplinary team may be vital, since currently there seems to be no one-size-fits-all approach for these patients.</p>","PeriodicalId":13711,"journal":{"name":"International heart journal","volume":" ","pages":"404-412"},"PeriodicalIF":1.2,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144077766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}